Geneva Biotech is a privately held biotechnology company, based in Geneva, Switzerland. Founded in 2012


Intelligent DNA delivery systems

Welcome Guest \\ Login

Our Services

Complex Gene Delivery Projects

We can design for pharmaceutical and biotech clients custom made vectors and work flows that enable delivery of complex, multigene cargos into diverse mammalian cells, primary cells and organs for a variety of applications. We have expertise in development of pseudotyping, target homing and cell entry strategies for the most difficult cell and organ types.


The 3 different primary cell lines above co-produce all 5 proteins. The first method for Multigene Delivery in Primary Cells_Nature Communications_2016

Custom Assay Development and Drug Discovery Services

Geneva Biotech have particular expertise at leveraging our multiprotein expression technologies for creating custom made, multi-component Signal Transduction Pathways for drug discovery. We also have expertise in production of multi-component Virus Like Particles (VLPs) for a variety of downstream drug discovery applications.

Signal Transduction Pathways

  • as templates for small molecule drug development
  • as templates for monoclonal antibody development
  • GPCR signaling cascades, kinase cascades

Virus Like Particles

  • as templates for small molecule drug development
  • as templates for monoclonal antibody development
  • as carriers for membrane proteins



Pentavalent Flu VLP Vaccine Candidate Created Using MultiBac™. Left: The core of the particle is comprised of the M1 and M2 proteins. The major immunogenic components of particle (HA1, HA2, and NA) are indicated by light ovals. The particle auto-assembles in cell culture following co-production of all protein subunits from one viral vector. Middle: Strategy for constructing a viral vector to produce the multiepitope flu VLP. Small circles (top) represent transfer plasmids which code for the indicated flu protein. Cre-Lox recombination (large X), fuses loxP sequences (small black spheres) present on both the transfer vector and baculovirus DNA (large oval, bottom). Using the generated vector, VLP production is then carried out in baculovirus-infected insect cells. Right: Electron micrograph of pentavalent influenza VLPs.

Research Highlights

our r&d View all

Latest News

DISTRIBUTOR IN CHINA Geneva Biotech is delighted to announce better services for our customers in China by teaming up with Equl LTD who have ...

View all

Contact Us